Safety and efficacy of Obinutuzumab with CHOP or bendamustine in previously untreated follicular lymphoma

Andrew Grigg, Martin J.S. Dyer, Marcos González Díaz, Martin Dreyling, Simon Rule, Guiyuan Lei, Andrea Knapp, Elisabeth Wassner-Fritsch, and Paula Marlton

Disclosures: AG received honoraria and accommodation support, and participated on an advisory board for F. Hoffmann-La Roche Ltd. MJSD received honoraria, research funding, and speaker’s fees, and participated in a consulting/advisory role for Roche Pharmaceuticals. MGD declares no competing financial interests. MD received honoraria and research funding, and participated in a consulting/advisory role for F. Hoffmann-La Roche Ltd. SR received research funding, travel/accommodation/expenses, and participated in a consulting/advisory role for Derriford Hospital, Plymouth, UK. AK and EWF are employees of F. Hoffmann-La Roche Ltd. GL is an employee of Roche Products Ltd. PM received honoraria, consulting fees, and travel/accommodation/expenses from F. Hoffmann-La Roche Ltd.

Contributions: MD, AK, and EWF were involved in the conception and design of the study. AG, MGD, AK, EWF, and PM were involved in data collection and assembly. AG, MJSD, MGD, MD, SR, GL, AK, EWF, and PM were involved in data analysis and interpretation. PM provided study materials or patients. All authors were involved in writing the manuscript and approved the final draft.